Get the Stockscreener App
5.28
2.75%
0.19
Cingulate Inc stock is traded at $5.28, with a volume of 84,846.
It is up +2.75% in the last 24 hours and up +15.20% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$5.09
Open:
$5.11
24h Volume:
84,846
Relative Volume:
0.20
Market Cap:
$76.49M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.239
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
-0.38%
1M Performance:
+15.20%
6M Performance:
-10.14%
1Y Performance:
+29.46%
1-Day Range:
$5.08
$5.315
1-Week Range:
$4.711
$5.35
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
5.26 | 74.02M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
516.12 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.07 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.31 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.08 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.55 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results - MarketBeat
Form 8K Cingulate Inc For: 13 August - Investing.com Nigeria
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Canada
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Canada
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com Nigeria
Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary - TradingView
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash - Quiver Quantitative
Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter - TradingView
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - marketscreener.com
Cingulate’s ADHD Drug Patent Protects Its Formulation Through 2042 - Stock Titan
Cingulate Inc. Warrants (CINGW) Rise 9.72% to $0.01 as Support and Resistance AlignSmall Cap Breakouts - dars.gov.et
Cingulate publishes pharmacokinetic study on ADHD drug candidate - Investing.com
Cingulate publishes pharmacokinetic study on ADHD drug candidate By Investing.com - Investing.com Canada
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile - GlobeNewswire
CING Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Cingulate (CING) Expected to Announce Earnings on Tuesday - MarketBeat
Cingulate Inc. Revenue Breakdown – BOATS:CINGW - TradingView
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CING) Stock News Today - TradingKey
Cingulate Inc. Warrants (CINGW) Fall 7.14% to $0.01 as Price Compresses at Key SupportKAMA Signal - dars.gov.et
Cingulate publishes phase 3 ADHD drug trial results in journal By Investing.com - Investing.com Nigeria
Cingulate Inc. Warrants (CINGW) Hold at $0.01 After 8.33% Gain as Speculative Interest PersistsLiquidity Order Flow - dars.gov.et
Cingulate Inc. Warrants (CINGW) Edge Lower as Trading Remains Tight Near $0.02IV Rank - dars.gov.et
Cingulate Inc (CING) Cash Flow - TradingKey
Cingulate Inc (CING) Income Statement - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CING|Cingulate Inc|Price:4.595|Chg%:-0.045 - TradingKey
Cingulate Inc (CING) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CING) Balance Sheet - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc. Revenue Breakdown – NASDAQ:CINGW - TradingView
CING|Cingulate Inc|Price:4.340|Chg%:-0.180 - TradingKey
CING|Cingulate Inc|Price:4.640|Chg%:-0.200 - TradingKey
CING|Cingulate Inc|Price:4.500|Chg%:-0.140 - TradingKey
Enterprise value to EBIT forward of Cingulate Inc. – NASDAQ:CINGW - TradingView
Cingulate (NASDAQ:CING) Stock Price Down 4.1%What's Next? - MarketBeat
Cingulate (NASDAQ: CING) to end Chief Legal Officer position, Patel departing - Stock Titan
Nilay Patel to Leave Cingulate as Chief Legal Officer Position Eliminated - TradingView
Cingulate (CING) Registration filing Summary - Quartr
Form 4 Cingulate Inc For: 21 July By Investing.com - Investing.com South Africa
CING Q1 2026 Earnings: Wider-Than-Expected Loss Masks Operational Progress, Shares RiseEarnings Call Q&A - po-news-eg.net
CING Q1 2026 Earnings: Wider-than-Expected Loss Reported; Stock Rises Despite No RevenueEarnings Trend Analysis - dars.gov.et
Cingulate enhances equity plan and updates board leadership - The Globe and Mail
Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information - Minichart
Cingulate Inc. Announces Board and Committee Changes, Effective July 9, 2026 - marketscreener.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cingulate Inc Stock (CING) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Werth Peter J. | Director |
Feb 06 '26 |
Buy |
5.04 |
19,455 |
98,053 |
117,449 |
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):